+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: Adaptive Trial Designs in IBD

  • PDF Icon

    Drug Pipelines

  • 27 Pages
  • August 2018
  • Region: Global
  • GlobalData
  • ID: 4701806
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.

Questions topics -
  • Current challenges in IBD clinical trials

  • Adaptive Phase II/III trial designs

  • Guselkumab’s Phase II/III trial in Crohn’s disease

  • Novel clinical trials in IBD

Key Highlights
  • Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical trials, both across Crohn’s disease & UC

  • Most KOLs flagged Phase II/III trials could accelerate development, but may limit ability to analyze data & adapt trial design

  • Most KOLs cited 8-12 weeks as being the minimum duration of a Phase II trial in IBD, with open-label extensions favored by all KOLs.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based

  • Interviews performed during July 2018

KOL data is analyzed to produce -
  • Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts

Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Adaptive trial designs in IBD

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary

  • Background

  • Research Panel Composition

  • Results & Implications

  • Appendix



Companies Mentioned

A selection of companies mentioned in this report includes:

  • Janssen

  • AbbVie

  • Gilead